User Evaluation of the MiniMed 620G and 640G Insulin Pumps

NCT ID: NCT01726621

Last Updated: 2016-04-18

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

55 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-03-31

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This six center international study will include two United Kingdom National Health Service centers, two centers in Melbourne, Australia and one center each in Denmark and Spain. The objective of the study is to evaluate subject acceptance of the a new insulin pump and transmitter together with the accompanying training materials. Descriptive data from participant questionnaires and device uploads will be evaluated.

Pediatric subjects between the ages of 7 - 18 years and adults from the age of 19 years of age upwards, who currently use an insulin pump in the management of their type 1 or type 2 diabetes, will be invited to participate. Each subject will be trained on the study device and then use it for approximately six weeks. During this time there will be three in-clinic visits and four follow-up phone calls, scheduled at the subjects' convenience. At the end of this period, they will revert back to their original insulin pump and complete a questionnaire on the study pump training materials, features and usability.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 1 Diabetes Type 2 Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Insulin dependent diabetics

Subjects currently using an insulin pump transferred to use the Medtronic MiniMed 620G and 640G insulin pumps and Guardian Link transmitter

Group Type OTHER

Medtronic MiniMed 620G or 640G Insulin Pump

Intervention Type DEVICE

Subjects to use the Medtronic MiniMed 620G or 640G Insulin Pump and Guardian Link transmitter to manage their diabetes for 4 - 6 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Medtronic MiniMed 620G or 640G Insulin Pump

Subjects to use the Medtronic MiniMed 620G or 640G Insulin Pump and Guardian Link transmitter to manage their diabetes for 4 - 6 weeks.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject is 7 years or older at time of screening
* Subject is current insulin pump user for at least 3 months
* Subject has the following Continuous Glucose Monitoring experience as determined by the Investigator:

* Has experience and is able to insert/change sensor by herself/himself and
* Has experience and can recharge the transmitter and
* Has experience and can read sensor data in real-time on her/his pump screen
* Subject has signed a Patient Informed Consent form and is willing to comply with the study procedures;
* Subject is willing to complete study questionnaires throughout the study
* Must have one of the following clinical diagnosis:

* Type 1 diabetes, for a minimum of 6 months prior to enrollment
* Insulin requiring type 2 diabetes, for a minimum of 6 months prior to enrollment

Exclusion Criteria

* Female subject has a positive urine pregnancy screening test.
* Female subject who plans to become pregnant during the course of study. If a woman becomes pregnant during participation, she will be withdrawn
* Subject has any condition that, in the opinion of the Investigator or qualified Investigational Center staff, may preclude him/her from participating in the study and completing study related procedures.
* Subject has impaired vision or hearing problems that could compromise the handling of the device as determined by Investigator or qualified Investigational Center staff
* Subject is actively participating in an investigational study (drug or device) wherein he/she has received treatment from an investigational study drug or investigational study device in the last 2 weeks.
Minimum Eligible Age

7 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medtronic Diabetes

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pratik Choudhary, MBBS, MRCP

Role: PRINCIPAL_INVESTIGATOR

King's College London

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

St Vincent Hospital and The University of Melbourne

Fitzroy, , Australia

Site Status

The Royal Melbourne Hospital

Patkville, , Australia

Site Status

Herlev Hospital

Herlev, , Denmark

Site Status

Barcelona University Hospital

Barcelona, , Spain

Site Status

University College Hospital

London, , United Kingdom

Site Status

King's College London

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Australia Denmark Spain United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CEP267

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study of LY900014 in a Medtronic Pump
NCT03760640 COMPLETED PHASE2